Recent News

• 03.31.2025 - VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
• 03.28.2025 - Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
• 03.27.2025 - Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
• 03.26.2025 - VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
• 03.25.2025 - VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
• 03.21.2025 - Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
• 03.20.2025 - Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
• 03.17.2025 - Volition Proudly Sponsors the 44th ISICEM Congress
• 03.13.2025 - Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
• 03.11.2025 - Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

Recent Filings

• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2025 - 8-K Current report
• 03.31.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.26.2025 - EX-99.1 EX-99.1
• 03.26.2025 - 8-K Current report
• 03.26.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities